Is CollPlant Biotechnologies Ltd. (CLGN) a Buy, Sell, or Hold?
CollPlant Biotechnologies Ltd.
NASDAQ:CLGN
$0.3493 USD
-$0.02 (-4.3%)
- Volume
- 17.39K
- Average Volume
- 87.47K
- Market Capitalization
- $4.53M
- P/E Ratio
- -0.34
- Dividend Yield
- 0.00%
- Price Target
- $12.50
- Year High
- $3.23
- Year Low
- $0.27
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.27
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Yehiel Tal |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CLGN |
| CUSIP | 19516R107 |
| CIK | 0001631487 |
| Web | https://www.collplant.com |
| Phone | 972 73 232 5600 |
| Currency | USD |
| Employees | 39 |
| Country | IL |
Liquidity
| Debt-to-Equity Ratio | 0.54 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.27 |
| Quick Ratio | 1.99 |
| Cash Ratio | 1.75 |
Sales & Book Value
| Annual Sales | $2.37M |
| Price / Sales | 11.64 |
| Cash Flow | -0.84 |
| Price / Cash Flow | -0.39 |
| Price / Book | 0.98 |
Price Target and Rating
| Average Stock Price Forecast | $12.50 |
| High Stock Price Forecast | $14.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -97.21% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.94 |
| Trailing P/E Ratio | -0.34 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-11.49M |
| Net Margin | -3376.35% |
| Pretax Margin | -3376.35% |
| Return on Equity | -160.28% |
| Return on Assets | -143.03% |
Financials Score
| AltmanZ Score | -23.05 |
| Piotroski Score | 1.00 |
| Working Capital | 3.1M |
| Total Assets | 9.18M |
| Ebit | -12.91M |
| Market Cap | 4.59M |
| Total Liabilities | 4.3M |
Poll Results
About CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Stock
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft ... tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
2026-06-30 08:00:00
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,647,061 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof), unregistered series A warrants to purchase up to 7,647,061 ordinary shares and unregistered series B warrants to purchase up to 15,294,122 ordinary shares, in a private placement at a combined purchase price of $0.34 per ordinary share and accompanying warrants (or $0.3399 per ordinary share equivalent and accompanying warrants). The series A warrants will have an exercise price of $0.34 per share, will be exercisable on the date of shareholder approval (the "Shareholder Approval Date") and will expire two years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants.
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
2026-05-29 08:00:00
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
2026-05-29 07:00:00
REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update. "In the first quarter of 2026, we initiated discussions with several leading strategic players to explore potential collaborations, primarily in the medical aesthetics field," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant Biotechnologies.
Frequently Asked Questions
-
What is the current CollPlant Biotechnologies Ltd. (CLGN) stock price?
-
CollPlant Biotechnologies Ltd.(NASDAQ:CLGN) stock price is $0.3493 in the last trading session. During the trading session, CLGN stock reached the peak price of $3.232 while $0.271 was the lowest point it dropped to. The percentage change in CLGN stock occurred in the recent session was --4.3% while the dollar amount for the price change in CLGN stock was -$-0.02.
-
CLGN's industry and sector of operation?
-
The NASDAQ listed CLGN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLGN?
-
Oren Fahimipoor | Vice President of Operations
Yehiel Tal | CEO & Chairman
Bar Abelis | Vice President of Legal
Hadas Dreiher Horowitz | Vice President of Human Resources
Oded Shoseyov | Founder & Chief Scientist -
How many employees does CLGN have?
-
Number of CLGN employees currently stands at 39. CLGN operates from Weizmann Science Park, Rehovot, TA 7670104, IL.
-
Link for CLGN official website?
-
Official Website of CLGN is: https://www.collplant.com
-
How do I contact CLGN?
-
CLGN could be contacted at phone #972 73 232 5600 and can also be accessed through its website. CLGN operates from Weizmann Science Park, Rehovot, TA 7670104, IL.
-
How many shares of CLGN are traded daily?
-
The average number of CLGN shares traded daily for last 3 months was 87.47K.
-
What is the market cap of CLGN currently?
-
The market value of CLGN currently stands at $4.53M with its latest stock price at $0.3493